The estimated Net Worth of Leiv Lea is at least 1.36 百万$ dollars as of 13 December 2022. Mr. Lea owns over 34,000 units of Corvus Pharmaceuticals Inc stock worth over 608,898$ and over the last 9 years he sold CRVS stock worth over 0$. In addition, he makes 749,828$ as Chief Financial Officer at Corvus Pharmaceuticals Inc.
Leiv has made over 4 trades of the Corvus Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 34,000 units of CRVS stock worth 25,500$ on 13 December 2022.
The largest trade he's ever made was buying 49,038 units of Corvus Pharmaceuticals Inc stock on 16 March 2022 worth over 76,990$. On average, Leiv trades about 8,883 units every 97 days since 2016. As of 13 December 2022 he still owns at least 133,238 units of Corvus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Lea stock trades at the bottom of the page.
Leiv Lea serves as Chief Financial Officer of the Company. Mr. Lea was a financial consultant from 2009 to November 2014. From 1998 to 2008, Mr. Lea served as Chief Financial Officer of Pharmacyclics, Inc. a biopharmaceutical company. From 1996 to 1997, he was a financial consultant. From 1986 to 1996, Mr. Lea served as Chief Financial Officer of Margaux, Inc., a refrigeration equipment manufacturer. He received a B.S. in Agricultural Economics from the University of California, Davis and an M.B.A. from the Anderson School at the University of California, Los Angeles.
As the Chief Financial Officer of Corvus Pharmaceuticals Inc, the total compensation of Leiv Lea at Corvus Pharmaceuticals Inc is 749,828$. There are 3 executives at Corvus Pharmaceuticals Inc getting paid more, with Daniel Hunt having the highest compensation of 1,554,080$.
Leiv Lea is 65, he's been the Chief Financial Officer of Corvus Pharmaceuticals Inc since 2019. There are 3 older and 14 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.
Leiv's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over 52,808,904$ worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth 85,214,510$ . The most active insiders traders include Holdings A/S Novo、Street Partners Llc Adams、Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of 1,530,854$. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth 34,600$.
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: